Publications by authors named "Michael Trevethick"

Claim this Profile
M
Molecular hybridization yields triazole bronchodilators for the treatment of COPD.
Lyn H Jones, Jane Burrows, Neil Feeder, Paul Glossop, Kim James, Michael A Trevethick

Bioorg Med Chem Lett· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhalation by design: novel tertiary amine muscarinic M₃ receptor antagonists with slow off-rate binding kinetics for inhaled once-daily treatment of chronic obstructive pulmonary disease.
Paul A Glossop, Christine A L Watson, David A Price, Mark E Bunnage, Donald S Middleton, Michael A Trevethick

J Med Chem· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhalation by design: dual pharmacology β-2 agonists/M3 antagonists for the treatment of COPD.
Lyn H Jones, Helen Baldock, Mark E Bunnage, Jane Burrows, Nick Clarke, Michael A Trevethick

Bioorg Med Chem Lett· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhalation by design: novel ultra-long-acting β(2)-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup.
Paul A Glossop, Charlotte A L Lane, David A Price, Mark E Bunnage, Russell A Lewthwaite, Michael A Trevethick

J Med Chem· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SAR of a series of inhaled A(2A) agonists and comparison of inhaled pharmacokinetics in a preclinical model with clinical pharmacokinetic data.
Simon J Mantell, Peter T Stephenson, Sandra M Monaghan, Graham N Maw, Michael A Trevethick

Bioorg Med Chem Lett· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhaled muscarinic antagonists for COPD--does an anti-inflammatory mechanism really play a role?
Michael Trevethick, Nicholas Clarke, Matthew Strawbridge, Michael Yeadon

Curr Opin Pharmacol· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A cell-based assay to assess the persistence of action of agonists acting at recombinant human beta(2) adrenoceptors.
Susan Summerhill, Timothy Stroud, Roshini Nagendra, Christelle Perros-Huguet, Michael Trevethick

J Pharmacol Toxicol Methods· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhaled adenosine A(2A) receptor agonists for the treatment of chronic obstructive pulmonary disease.
Simon J Mantell, Peter T Stephenson, Sandra M Monaghan, Graham N Maw, Michael A Trevethick

Bioorg Med Chem Lett· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Highly potent and selective zwitterionic agonists of the delta-opioid receptor. Part 1.
Donald S Middleton, Graham N Maw, Clare Challenger, Alan Jessiman, Patrick S Johnson, Michael Trevethick

Bioorg Med Chem Lett· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease.
Katharine H Banner, Michael A Trevethick

Trends Pharmacol Sci· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis